Ablenio is currently seeking investments or partners to advance its pipeline of anti-complement antibodies. Our lead candidates are now moving to Phase II clinical trial in Q2 of 2022 for various clinical indications. Our primary indication is PNH but given the unique mechanism of action associated with our antibody platform it has the potential to address a number of additional clinical indications. Ablenio is open to discussions for the license of a subset, or the entire complement platform for one or more indications.

Value  Propositions:        
        - Phase I  clinical trial for NM8074 to complete in Q1, 2022
        - Advanced  stage antibody platform has the potential to address multiple  indications    
        - Strong intellectual  property with a number of current and pending patents    

           We are very interested in licensing our drugs to a partner for their development as novel therapies for rare diseases

‍